RUNX1 and acute lymphoblastic leukemia: This is further underlined by the results of the Children’s Oncology Group AALL0331 Study in low risk ALL of which 577 (62.1%) of the 929 included patients was ETV6::RUNX1 positive showing 6-year event free survival of 94.0% (± 0.8%) and overall survival of 99.2% (± 0.3%) despite a maximum of 4 weeks of asparagine depletion, a three-drug induction and no intensive consolidation [34].